Price T Rowe Associates Inc Lyra Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 17,541 shares of LYRA stock, worth $4,911. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,541Holding current value
$4,911% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LYRA
# of Institutions
58Shares Held
31.7MCall Options Held
316KPut Options Held
600-
Perceptive Advisors LLC New York, NY12.8MShares$3.57 Million0.1% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.77MShares$1.34 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.83MShares$792,3930.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.78MShares$778,4730.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.73MShares$484,6560.0% of portfolio
About Lyra Therapeutics, Inc.
- Ticker LYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,826,400
- Market Cap $8.91M
- Description
- Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...